30 results about "Cell Migration Inhibition" patented technology

Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

The present invention relates to a method for predicting the risk of a subject developing a cardiovascular event comprising detecting at least one biomarker in (a sample of) the cardiovascular system from said subject, wherein said biomarker comprises at least one protein selected from the group consisting of Tumor Necrosis Factor Alpha Precursor; Lysosomal-associated Membrane Protein (1); Interleukin-5 Precursor; Interleukin-6 Precursor; C-C Motif Chemokine (2) Precursor; C-C Motif Chemokine (5) Precursor RANTES; Cathepsin L1 Precursor; Adenylate Kinase (1); Leukotriene B4 Receptor (1); Complement Factor D; Secreted Phosphoprotein (1); Small Inducible Cytokine A17 Precursor; C-X-C Motif Chemokine (10) Precursor; Tumor Necrosis Factor Ligand Superfamily Member (11)(RANKL); C-C Motif Chemokine (18) Precursor; 72 kDa Type IVCollagenase Precursor; Neutrophil Collagenase Precursor; fatty acid binding protein (4); calpain (2), (m/II) large subunit; Macrophage Migration Inhibitory Factor; Cathepsin S Precursor; Interleukin (13) Precursor; and soluble ICAM-1.

The invention relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines, belongs to the field of biopharmaceutical research, and particularly relates to an application of a PNO1 inhibitor to preparation of esophagus cancer treatment medicines. The inventor firstly finds that the PNO1 can be used as an esophagus cancer treatment target point. The PNO1 inhibitor can restrain the proliferation rate of esophagus cancer cells, can restrain the cloning and forming capacity of the esophagus cancer cells, can promote esophagus cancer apoptosis, can restrain esophagus cancer cell migration, can restrain esophagus cancer cell transfer, and can restrain esophagus cancer cell invasion and transfer, so as to treat esophagus cancer, and a new direction is opened up for treatment of esophagus cancer.

Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.

The specification provides methods of preparing high-affinity antibodies to a macrophage migration inhibitory factor (MIF) in animals in which the MIF gene has been homozygously knocked-out (MIF^−/−). Also provided are methods of preparing hybridomas which produce the anti-MIF antibodies, methods of administering the antibodies to treat inflammatory or cancerous conditions and/or diseases modulated by MIF, as well as compositions comprising said high-affinity anti-MIF antibodies.

Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and/or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.

The invention provides a preparation method and a use of a medicine over-expressing a PCNP gene. The medicine includes a plasmid over-expressing the PCNP gene and a PCNP protein obtained through the over-expression of the PCNP gene. The construction method of the plasmid over-expressing the PCNP gene comprises the following steps: designing a primer according to the sequence of the PCNP gene, andcarrying out PCR amplification on a target gene; carrying out enzyme digestion on restriction enzyme digestion sites Xho I and Kpn I in a GV230 vector to form a linearized GV230 vector; and connectingthe target gene with the linearized GV230 vector to construct a GV230-PCNP vector which is the plasmid over-expressing the PCNP gene. When the medicine over-expressing the PCNP gene is used in humanneuroblastoma cells, the overexpression of the PCNP gene in the human neuroblastoma cells can promote apoptosis, inhibit cell growth, inhibit cell migration and inhibit the growth of human neuroblastomas.

Disclosed are peptides capable of enzymatically-induced self-assembly to which is conjugated a redox modulator. These peptides are enzymatically responsive hydrogelators, and they can be used to form pericellular hydrogels/nanofibrils upon exposure to target cells that secrete or express a surface bound ectoenzyme having hydrolase activity suitable to induce peptide gelation. These materials, and compositions containing the same, can be used for inhibiting cancer cell migration, inhibiting cancer cell survival, and/or inhibiting cancer cell growth.

The invention discloses pharmaceutical application of pawpaw total triterpenes. The invention specifically comprises application of pawpaw total triterpenes in preparing medicines for promoting cell proliferation and cell migration of human skin fibroblast HDF with UVB injury and inhibiting cell apoptosis, application in preparing medicines for promoting cell proliferation and cell migration of human umbilical vein endothelial cells HUVECs with UVB injury and inhibiting cell apoptosis, application in preparing medicines for treating postoperative cut injury wound healing and application in preparing medicines for treating injured skin regeneration and repair. The pawpaw total triterpenes have a remarkable treatment effect.

In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating inflammatory disease, neurological disorders and cancer using the compounds of the invention.

Provided are tumor marker aquaporin 2 protein and an application thereof, belonging to the fields of tumor detection and molecular targeted therapy. Embodiments include applications of the aquaporin 2 protein in the following functions: (1) as a new tumor marker used for the early diagnosis and prognostic determination of malignant tumors including head and neck squamous cell carcinoma, kidney cancer and prostate cancer; (2) inhibiting tumor cell proliferation; (3) inhibiting tumor cell migration; (4) inhibiting animal transplant tumor model growth. Targeted therapy which uses the aquaporin 2 protein as a biomarker, as in the embodiments of the present invention, provides new ideas for the treatment of malignant tumors such as head and neck squamous cell carcinoma, kidney cancer and prostate cancer.

This invention relates to a pharmaceutical agent for preventing metastasis of cancer, which comprises a substance that inhibits expression of macrophage migration inhibitory factor (MIF). Such substance includes siRNA of MIF.